Patent ID: 7763243

Claim:
A method for treatment of a patient suffering from cancer, said method comprising the steps of: (a) isolating a sample of blood mononuclear cells, comprising T cells; (b) activating one or more of said T cells by ex vivo stimulation with soluble anti-CD3 monoclonal antibody, and growth of said activated T cells in the presence of between 100 IU/ml to 500 IU/ml of IL-2; (c) arming of said activated T cells with bispecific antibodies capable of binding to a T cell receptor complex of a T cell, and to tumor-associated antigens on a tumor cell, under conditions wherein; (i) said bispecific antibody binds to said T cells and tumor cells, and/or Fc-receptor positive cells and tumor cells, (ii) said bispecific antibody binds to the tumor target and said antibody binding to the tumor target activates said T cells, (iii) said bispecific antibody redirects said T cells and/or Fc-receptor positive cells to said tumor cells, (iv) said activated and armed T cells destroy said tumor cells; and, (d) reinfusing a composition of cells comprising said activated T cell armed with said bispecific antibody into the patient as treatment for the patient, and either: (i) contacting T cells specific for different epitopes on the tumor cell, with the composition of cells and inducing proliferation of the T cells specific for different epitopes on the tumor cell, or (ii) targeting and contacting multiple target cells with the armed T cell to which the bispecific antibody remains bound and killing said multiple target cells.